NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP ) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 16th Annual Biotech in Europe Forum being held on September 27-28, 2016 in Basel, Switzerland by Sachs Associates.
Ronald Notvest, Ph.D., Executive Vice President, Commercial Planning and Development at Tonix, will provide a corporate update and an overview of Tonix’s PTSD clinical program. Tonix recently announced a successful end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) and also positive data from its randomized, double-blind, placebo-controlled Phase 2 AtEase clinical trial evaluating TNX-102 SL in military-related PTSD. Dr. Notvest will discuss expected next steps for this program.
| Event: | Sachs 16th Annual Biotech in Europe Forum |
| Date: | Tuesday, September 27, 2016 |
| Time: | 4:45pm CEST (Central European Summer Time) |
| Location: | Presentation Track G: Darwin Room, Congress Center, Basel, Switzerland |
TNX-102 SL is an Investigational New Drug and has not been approved for any indication.
About Tonix Pharmaceuticals Holding Corp. Tonix is developing next-generation medicines for common disorders of the central nervous system, with its lead program focusing on PTSD. This disorder is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. This press release and further information about Tonix can be found at www.tonixpharma.com .
Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2016, and future periodic reports filed with the SEC on or after the date hereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
Contacts Bradley J. Saenger, CPA Chief Financial Officer investor.relations@tonixpharma.com (212) 980-9155 x107 Jessica Smiley Investor Relations investor.relations@tonixpharma.com (212) 980-9155 x185 Edison Advisors (investors) Tirth Patel tpatel@edisongroup.com (646) 653-7035 Dian Griesel Int’l (media) Susan Forman / Laura Radocaj sforman@dgicomm.com iradocaj@dgicomm.com (212) 825-3210
